Zonisep 50 Capsule contains Zonisamide 50 mg, an antiepileptic agent indicated for the management of partial seizures in adults and pediatric patients. Zonisamide acts by stabilizing neuronal membranes and suppressing abnormal electrical activity in the brain through multiple mechanisms, including blockade of voltage-dependent sodium and T-type calcium channels. This dual action reduces the frequency and severity of seizure episodes. Zonisep 50 is typically used as adjunctive therapy in patients with refractory partial seizures who have not achieved adequate control with other antiepileptic drugs. The capsule formulation allows for convenient oral administration with good bioavailability. Dosage should be individualized based on clinical response and tolerability, with gradual titration recommended to minimize adverse effects. Common side effects may include dizziness, somnolence, headache, and gastrointestinal disturbances. Rare but serious adverse reactions such as metabolic acidosis, hypersensitivity, and renal calculi have been reported, necessitating regular monitoring of renal function and metabolic parameters during therapy. Zonisep 50 should be used cautiously in patients with sulfonamide allergy, hepatic or renal impairment, and in pregnant or breastfeeding women unless the potential benefits outweigh risks. Concomitant use with other central nervous system depressants may potentiate sedation. Overall, Zonisep 50 Capsule is a valuable option in the comprehensive management of partial epilepsy.